Search

Yeast

Yeast allergenic extract is used in allergenic testing.

Belimumab

[A251520] It is currently used to treat SLE and lupus nephritis.[L42630] … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.

Scorpion (centruroides) immune Fab2 antivenin (equine)

This drug is a polyvalent antivenin proven to be useful against scorpion stings. … Most commonly, children experience severe reactions, however, adults can be affected, too [L2195], [L2196], [L2198].

TOL-101

Trastuzumab

It displays biosimilar properties as Herceptin according to clinical data. … Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly [A121].

Human C1-esterase inhibitor

The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]

Mifamurtide

The adverse events (AEs) associated with mifamurtide were generally mild to moderate in severity [A31748]. … The overall result of MDP recognition leads to the production of proinflammatory cytokines and promotion of bactericidal and tumoricidal effects [A31745].

Inotuzumab ozogamicin

Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects

Risdiplam

[L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless … This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene

Oseltamivir

to outweigh the small clinical benefit of use of oseltamivir. … Notably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness.